CG Oncology director Leonard Post plans $186K share sale
The notice links the proposed sale to stock options expected to be exercised over the next three months.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
CG Oncology, Inc. (CGON) lists director Leonard Post’s planned sale of 3,000 common shares, with an aggregate market value of $185,520 and a listed sale date of October 15, 2026. The shares are to be received through stock-option exercises over the next three months; the notice says acquisition and payment dates were and will be the exercise/sale dates. It lists 88,640,375 shares outstanding. Morgan Stanley Smith Barney LLC is listed as broker, and NASDAQ is listed as the market.
Two prior Rule 10b5-1 sales are reported: 1,000 shares on September 15, 2026, for $72,982.80, and 1,000 shares on August 14, 2026, for $74,540.00.
Key Figures
Key Terms
Rule 144 regulatory
10b5-1 Sales regulatory
stock options financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What recent CGON sales by Leonard Post are reported?
AI-generated analysis. How Rhea-AI works. Not financial advice.